

1645



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

#6 Plunkett  
17/10/03  
RECEIVED  
TECH CENTER 1600/2900  
01 2003

<b>INFORMATION DISCLOSURE STATEMENT</b>		Docket Number: <b>12178/2</b>	
Application Number <b>10/070,480</b>	Filing Date <b>July 8, 2002</b>	Examiner	Art Unit <b>1645</b>
Invention Title <b>STEREOSTRUCTURE OF DECARBAMYLASE AND USES THEREOF</b>		Inventor(s) <b>NAKAI et al.</b>	

Address to:  
Commissioner for Patents  
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks, Washington, D.C. 20231.

Date: April 25, 2003


Signature: Elizabeth M. Wieckowski  
Elizabeth M. Wieckowski, Reg. No. 42,226

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. Applicant's attorney certifies that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of information disclosure statement.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: April 25, 2003

By: Elizabeth M. Wieckowski  
Elizabeth M. Wieckowski, Reg. No. 42,226

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
Modified PTO Form 1449

ATTY. DOCKET NO.  
12178/2

SERIAL NO.  
10/070180

APPLICANT  
NAKAI et al.

FILING DATE  
July 8, 2002

GROUP  
1645

**RECEIVED**  
MAY 01 2003  
TECH CENTER 1600/2900

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	5,565,344	October 15, 1996	Nanba et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS**

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Hilgenfeld et al., "Crystallization of Blood Coagulation Factor XIII by an automated procedure", FEBS Letters, vol. 265, no. 1,2 (June 1990), pgs. 110-112

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	